FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026726039> ?p ?o ?g. }

• W2026726039 endingPage "395" @default.
• W2026726039 startingPage "388" @default.
• W2026726039 abstract "To develop clinical practice guidelines for the use of methotrexate in rheumatoid arthritis (RA), using the evidence-based approach and expert opinion. A scientific committee used a Delphi procedure to select five questions, which formed the basis for developing recommendations. Evidence providing answers to the five questions was sought in the Cochrane databases, PubMed, and proceedings of meetings of the French Society for Rheumatology, European League Against Rheumatism, and American College of Rheumatology. Using this evidence, a group of rheumatologists developed and validated the recommendations. For each recommendation, the level of evidence and the extent of agreement among experts were specified. The recommendations were as follows: 1: The starting dosage for methotrexate in patients with RA should not be less than 10 mg/week and should be determined based on disease severity and patient-related factors; 2: When a patient with RA shows an inadequate response to methotrexate, the dosage should be increased at intervals of 6 weeks, up to 20 mg/week, according to tolerance and patient-related factors; 3: When starting methotrexate treatment in a patient with RA, preference should be given to the oral route. A switch to the intramuscular or subcutaneous route should be considered in patients with poor compliance, inadequate effectiveness, or gastrointestinal side effects; 4: At present, there is no evidence indicating that a change in methotrexate dosage is in order when a TNF antagonist is given concomitantly; 5: The investigations that are mandatory before starting methotrexate therapy in a patient with RA consist of a full blood cell count, serum transaminase levels, serum creatinine with computation of creatinine clearance, and a chest radiograph. In addition, serological tests for the hepatitis viruses B and C and a serum albumin assay are recommended. In patients with a history of respiratory disease or current respiratory symptoms, lung function tests with determination of the diffusing capacity for carbon monoxide are recommended; 6: Investigations that are mandatory for monitoring methotrexate therapy in patients with RA consist of full blood cell counts and serum transaminase and creatinine assays. These tests should be obtained at least once a month for the first 3 months then every 4–12 weeks; 7: Folate supplementation can be given routinely to patients treated with methotrexate for RA. In practice, a minimal dosage of 5 mg of folic acid once a week, at a distance from the methotrexate dose, is appropriate; 8: In the event of respiratory symptoms possibly related to methotrexate toxicity, the drug must be stopped and symptom severity evaluated. Should evidence of serious disease be found, the patient should be admitted immediately or advice from a pulmonologist should be obtained immediately. Recommendations about methotrexate therapy for RA were developed. These recommendations should help to improve practice uniformity and, ultimately, to improve the management of RA." @default.
• W2026726039 created "2016-06-24" @default.
• W2026726039 creator A5008811878 @default.
• W2026726039 creator A5022620505 @default.
• W2026726039 creator A5031211618 @default.
• W2026726039 creator A5033486865 @default.
• W2026726039 creator A5051196993 @default.
• W2026726039 creator A5057763735 @default.
• W2026726039 creator A5060793051 @default.
• W2026726039 creator A5068131579 @default.
• W2026726039 creator A5073154423 @default.
• W2026726039 creator A5073579921 @default.
• W2026726039 creator A5076446601 @default.
• W2026726039 creator A5077099389 @default.
• W2026726039 creator A5080881858 @default.
• W2026726039 creator A5086242828 @default.
• W2026726039 creator A5086550404 @default.
• W2026726039 creator A5091097919 @default.
• W2026726039 creator A5091895459 @default.
• W2026726039 date "2006-07-01" @default.
• W2026726039 modified "2023-10-05" @default.
• W2026726039 title "Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion" @default.
• W2026726039 cites W1968380478 @default.
• W2026726039 cites W1977252928 @default.
• W2026726039 cites W1978576762 @default.
• W2026726039 cites W1979364075 @default.
• W2026726039 cites W1985763670 @default.
• W2026726039 cites W1991393467 @default.
• W2026726039 cites W1994277369 @default.
• W2026726039 cites W1995228104 @default.
• W2026726039 cites W1996472975 @default.
• W2026726039 cites W2002265278 @default.
• W2026726039 cites W2010707109 @default.
• W2026726039 cites W2010886512 @default.
• W2026726039 cites W2013790828 @default.
• W2026726039 cites W2013864512 @default.
• W2026726039 cites W2015228675 @default.
• W2026726039 cites W2020033130 @default.
• W2026726039 cites W2022225387 @default.
• W2026726039 cites W2024197152 @default.
• W2026726039 cites W2039780343 @default.
• W2026726039 cites W2045952018 @default.
• W2026726039 cites W2054888624 @default.
• W2026726039 cites W2055280685 @default.
• W2026726039 cites W2058697685 @default.
• W2026726039 cites W2069514277 @default.
• W2026726039 cites W2070869629 @default.
• W2026726039 cites W2080638211 @default.
• W2026726039 cites W2096258335 @default.
• W2026726039 cites W2105367456 @default.
• W2026726039 cites W2114485875 @default.
• W2026726039 cites W2115004354 @default.
• W2026726039 cites W2115068422 @default.
• W2026726039 cites W2121261755 @default.
• W2026726039 cites W2123035329 @default.
• W2026726039 cites W2125574445 @default.
• W2026726039 cites W2134387478 @default.
• W2026726039 cites W2135368653 @default.
• W2026726039 cites W2151350560 @default.
• W2026726039 cites W2151884828 @default.
• W2026726039 cites W2156702654 @default.
• W2026726039 cites W2163089977 @default.
• W2026726039 cites W2168681431 @default.
• W2026726039 cites W2314052274 @default.
• W2026726039 cites W2331320446 @default.
• W2026726039 cites W334564628 @default.
• W2026726039 cites W4361867558 @default.
• W2026726039 doi "https://doi.org/10.1016/j.jbspin.2006.01.007" @default.
• W2026726039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16626993" @default.
• W2026726039 hasPublicationYear "2006" @default.
• W2026726039 type Work @default.
• W2026726039 sameAs 2026726039 @default.
• W2026726039 citedByCount "128" @default.
• W2026726039 countsByYear W20267260392012 @default.
• W2026726039 countsByYear W20267260392013 @default.
• W2026726039 countsByYear W20267260392014 @default.
• W2026726039 countsByYear W20267260392015 @default.
• W2026726039 countsByYear W20267260392016 @default.
• W2026726039 countsByYear W20267260392017 @default.
• W2026726039 countsByYear W20267260392018 @default.
• W2026726039 countsByYear W20267260392019 @default.
• W2026726039 countsByYear W20267260392020 @default.
• W2026726039 countsByYear W20267260392021 @default.
• W2026726039 countsByYear W20267260392022 @default.
• W2026726039 countsByYear W20267260392023 @default.
• W2026726039 crossrefType "journal-article" @default.
• W2026726039 hasAuthorship W2026726039A5008811878 @default.
• W2026726039 hasAuthorship W2026726039A5022620505 @default.
• W2026726039 hasAuthorship W2026726039A5031211618 @default.
• W2026726039 hasAuthorship W2026726039A5033486865 @default.
• W2026726039 hasAuthorship W2026726039A5051196993 @default.
• W2026726039 hasAuthorship W2026726039A5057763735 @default.
• W2026726039 hasAuthorship W2026726039A5060793051 @default.
• W2026726039 hasAuthorship W2026726039A5068131579 @default.
• W2026726039 hasAuthorship W2026726039A5073154423 @default.
• W2026726039 hasAuthorship W2026726039A5073579921 @default.
• W2026726039 hasAuthorship W2026726039A5076446601 @default.
• W2026726039 hasAuthorship W2026726039A5077099389 @default.

• next